

## Supplementary information

### **A multi-ancestry GWAS of Fuchs corneal dystrophy highlights the contributions of laminins, collagen, and endothelial cell regulation**


Bryan R. Gorman<sup>1,2,28</sup>, Michael Francis<sup>1,2,28</sup>, Cari L. Nealon<sup>3</sup>, Christopher W. Halladay<sup>4</sup>, Nalvi Duro<sup>1,2</sup>, Kyriacos Markianos<sup>1</sup>, Giulio Genovese<sup>5,6,7</sup>, Pirro Hysi<sup>8,9,10</sup>, H el ene Choquet<sup>11</sup>, Natalie A. Afshari<sup>12</sup>, Yi-Ju Li<sup>13</sup>, VA Million Veteran Program\*, J. Michael Gaziano<sup>14,15</sup>, Adriana M. Hung<sup>16,17,18</sup>, Wen-Chih Wu<sup>19</sup>, Paul B. Greenberg<sup>20,21</sup>, Saiju Pyarajan<sup>1</sup>, Jonathan H. Lass<sup>22</sup>, Neal S. Peachey<sup>23,24,25,29</sup>, Sudha K. Iyengar<sup>23,26,27,29</sup>

<sup>1</sup>Center for Data and Computational Sciences (C-DACS), VA Boston Healthcare System, Boston, MA, USA; <sup>2</sup>Booz Allen Hamilton, McLean, VA, USA; <sup>3</sup>Eye Clinic, VA Northeast Ohio Healthcare System, Cleveland, OH, USA; <sup>4</sup>Center of Innovation in Long Term Services and Supports, Providence VA Medical Center, Providence, RI, USA; <sup>5</sup>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA; <sup>6</sup>Stanley Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA; <sup>7</sup>Department of Genetics, Harvard Medical School, Boston, MA, USA; <sup>8</sup>Department of Ophthalmology, King's College London, London, UK; <sup>9</sup>Department of Twins Research and Genetic Epidemiology, King's College London, London, UK; <sup>10</sup>UCL Great Ormond Street Hospital Institute of Child Health, King's College London, London, UK; <sup>11</sup>Division of Research, Kaiser Permanente Northern California (KPNC), Oakland, CA, USA; <sup>12</sup>Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, CA, USA; <sup>13</sup>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA; <sup>14</sup>Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA; <sup>15</sup>Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; <sup>16</sup>Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; <sup>17</sup>Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, TN, USA; <sup>18</sup>VA Tennessee Valley Healthcare System, Nashville, TN, USA; <sup>19</sup>Cardiology Section, Medical Service, Providence VA Medical Center, Providence, RI, USA; <sup>20</sup>Ophthalmology Section, Providence VA Medical Center, Providence, RI, USA; <sup>21</sup>Division of Ophthalmology, Alpert Medical School, Brown University, Providence, RI, USA; <sup>22</sup>Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH, USA; <sup>23</sup>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA; <sup>24</sup>Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; <sup>25</sup>Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; <sup>26</sup>Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA; <sup>27</sup>Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA




\*Lists of authors and their affiliations appear at the end of the paper.

<sup>28</sup>These authors contributed equally to this work.



<sup>29</sup>These authors jointly supervised this work.



**Supplementary Fig. 1. Manhattan and quantile-quantile (QQ) plots.** **Left:** Manhattan plots showing  $-\log_{10}(p)$  for associations of genetic variants with Fuchs endothelial corneal dystrophy in (a) European, (b) admixed African, and (c) Hispanic/Latino Million Veteran Program (MVP) cohorts. The red line indicates the genome-wide significance threshold ( $P < 5 \times 10^{-8}$ ). Novel loci are highlighted in red while known loci are highlighted in blue. Y-axis breaks in (a) are used to include the most significant variant at *TCF4*. **Right:** QQ plots showing observed versus expected distributions of association *P*-values.


**a****b**

**Supplementary Fig. 2. Meta-analysis Manhattan and quantile-quantile (QQ) plots.** (a) Manhattan and QQ plot for European-only meta-analysis of MVP European and Afshari et al.<sup>1</sup> cohorts. The red line indicates the genome-wide significance threshold ( $P < 5 \times 10^{-8}$ ). Novel loci are highlighted in red while known loci are highlighted in blue. A Y-axis break is used to include the most significant variant at *TCF4*. (b) QQ plot for multi-ancestry meta-analysis (corresponding Manhattan plot shown in Main Figure 2).



**a****b**

**Supplementary Fig. 3. Comparison of allele effect sizes.** Scatterplots comparing effect sizes (logarithm of odds ratios and 95% confidence interval) of previously reported (blue) and novel (pink) lead SNPs between **(a)** Million Veteran Program (MVP) European (EUR) and Afshari et al.<sup>1</sup>, and **(b)** MVP admixed African (AFR) vs MVP EUR. Directions of effects estimates between cohorts were consistent for all lead SNPs except one, rs12439253 (*RORA*), which was not significant in AFR.









**Supplementary Fig. 4. Regional Manhattan plot and forest plot for *SSBP3*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.





**Supplementary Fig. 5. Regional Manhattan plot and forest plot for *KANK4*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.




**Supplementary Fig. 6. Regional Manhattan plot and forest plot for *ATP1B1*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.




**Supplementary Fig. 7. Regional Manhattan plot and forest plot for *LAMC1*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.



**Supplementary Fig. 8. Regional Manhattan plot and forest plot for *THSD7A*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.





**Supplementary Fig. 9. Regional Manhattan plot and forest plot for *LAMB1*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.




**Supplementary Fig. 10. Regional Manhattan plot and forest plot for *PNPLA2/PIDD1*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.






**Supplementary Fig. 11. Regional Manhattan plot and forest plot for *RORA*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.








**Supplementary Fig. 12. Regional Manhattan plot and forest plot for *HS3ST3B1*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.




**Supplementary Fig. 13. Regional Manhattan plot and forest plot for *TCF4*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.




**Supplementary Fig. 14. Regional Manhattan plot and forest plot for *LAMA5*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.




**Supplementary Fig. 15. Regional Manhattan plot and forest plot for *COL18A1*.** (a) LocusZoom regional Manhattan plot showing variant-level associations and local linkage disequilibrium (LD) structure of a significant multi-ancestry meta-analysis FECD genomic risk locus. Plots are presented in the order of their genomic coordinates. A European LD reference panel (1000 genomes) was used to color points in all plots. (b) Odds ratios (OR) and 95% confidence intervals for FECD at lead SNPs in Million Veteran Program European (EUR), admixed African (AFR), and Afshari<sup>1</sup> cohorts, and combined multi-ancestry meta-analysis (Meta). OR is not shown for six of twelve AFR index variants which did not meet the meta-analysis minor allele frequency cutoff of  $\geq 1\%$ ; for these variants, “Meta” refers to the EUR-only meta-analysis.




**Supplementary Fig. 16. Novel causal variant prediction at *LAMB1*.** Local Manhattan plots, finemapping posterior inclusion probabilities, Combined Annotation Dependent Depletion (CADD) scores, and RegulomeDB scores for significant Fuchs endothelial corneal dystrophy associations in the European meta-analysis.



**Supplementary Fig. 17. Novel causal variant prediction at *LAMA5*.** Local Manhattan plots, finemapping posterior inclusion probabilities, Combined Annotation Dependent Depletion (CADD) scores, and RegulomeDB scores for significant Fuchs endothelial corneal dystrophy associations in the European meta-analysis.




**Supplementary Fig. 18. Novel causal variant prediction at *PIDD1*.** Local Manhattan plots, finemapping posterior inclusion probabilities, Combined Annotation Dependent Depletion (CADD) scores, and RegulomeDB scores for significant Fuchs endothelial corneal dystrophy associations in the European meta-analysis.




**Supplementary Fig. 19. rs11659764 variant-level PheWAS.** Phenome-wide associations with rs11659764, the lead Fuchs endothelial corneal dystrophy (FECD) variant at *TCF4*. Phenotypes are grouped by category those reaching multiple testing corrected significance ( $P < 2.9 \times 10^{-6}$ ; red line) are labeled. Point direction indicates positive or negative effect. Y-axis break indicates switch to logarithmic scale. FECD (not shown) had the most significant association ( $P = 5.01 \times 10^{-658}$ ). All lab measures were rank inverse normal transformed.





**Supplementary Fig. 20. Colocalization with renal traits at *TCF4*.** Left: For Million Veteran Program EUR participants, regional Manhattan plots at the *TCF4* locus with FECD, serum bicarbonate, serum chloride, serum potassium, and urinary albumin-to-creatinine ratio. Right: Effects comparison scatterplots for variants in the *TCF4* locus (chr18:54,500,000 to 56,500,000; only those points with  $P < 0.001$ ) and 95% confidence interval (c.i.). FECD effects are shown as logarithm of odds ratios. Trendline, correlation coefficients ( $r$ ) and associated  $P$ -values are shown for scatterplots. 21



**Supplementary Fig. 21. Predicted impact of mutation on LE domain structure.** Missense mutations associated with risk of Fuchs endothelial corneal dystrophy in **(a)** and **(b)** are colored orange. **(a)** The homolog template for α5 does not cover the entire target sequence, hence the predicted homology model does not include a portion of the domain. However, given the excellent agreement between the AlphaFold 2 (AF2) prediction and the homology model for the existing portion of the domain of α5 LE22, it is likely that AF2 is providing a feasible conformation of the α5 LE22 loop missing in the template structure. **(b)** The AF2 prediction for β1 LE6 has excellent agreement with the crystallized rat homolog (67% sequence identity) as well as the SWISS-MODEL homology model. **(c)** AF2 prediction of β1 LE6 with four disulfide links that fortify the tertiary structure of the domain displayed as yellow sticks. **(d)** Change in hydrogen bond content and Gibbs free energy introduced by the mutations. The substitution of a glycine with glutamic acid in A5 LE22 does not result in loss or gain of hydrogen bonds within the domain. Meanwhile, the replacement of the arginine by a glycine in β1 LE6 results in a loss of 3 hydrogen bonds.

## Supplementary References

1. Afshari, N. A. *et al.* Genome-wide association study identifies three novel loci in Fuchs endothelial corneal dystrophy. *Nat. Commun.* **8**, 14898 (2017).